ImageneBio/$IMA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ImageneBio
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
- Ticker
- $IMA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 18
- Headquarters
- San Diego, United States
- Website
- www.inmagenebio.com
ImageneBio Metrics
BasicAdvanced
$42M
-
-$3.29
-
-
Price and volume
Market cap
$42M
52-week high
$8.70
52-week low
$3.60
Average daily volume
12K
Financial strength
Current ratio
16.173
Quick ratio
15.678
Total debt to equity
0.01
Profitability
EBITDA (TTM)
-49.386
Effective tax rate (TTM)
0.53%
Management effectiveness
Return on assets (TTM)
-20.63%
Return on equity (TTM)
-32.34%
Valuation
Price to book
0.36
Price to tangible book (TTM)
0.36
Price to free cash flow (TTM)
-1.205
Free cash flow yield (TTM)
-83.00%
Free cash flow per share (TTM)
-3.088
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-30.99%
What the Analysts think about ImageneBio
Analyst ratings (Buy, Hold, Sell) for ImageneBio stock.
Analyst projections of the future price of ImageneBio stock.
ImageneBio Financial Performance
Revenues and expenses
ImageneBio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.